Skip to main content
. 2010 Jan 15;10:18. doi: 10.1186/1471-2407-10-18

Table 1.

Percentages of patients showing positive immunohistochemical reactions to c-IAP-2, c-IAP-1/2 and ILP in normal prostate (NP), benign prostatic hyperplasia (BPH), prostatic carcinoma (PC) and average optical densities of immunostaining in positive patients.

c-IAP-1/2 c-IAP-2 ILP
Prostates (no.) Positive cases (%) Optical density Positive cases (%) Optical density Positive cases (%) Optical density

Normal (20) 80 19.64 ± 1.06 60 8.94 ± 0.61a 20 5.39 ± 1.18a

BPH (33) 57.57 18.36 ± 3.29 57.57 14.30 ± 1.2b 66.6 17.91 ± 1.44b

PIN
 Low grade PIN (12) 58.37 18.04 ± 1.29 66.6 9.83 ± 0.9a 66.6 7.26 ± 1.01a
 High grade PIN (15) 60 18.91 ± 1.69 46.6 15.33 ± 1.52b 80 23.14 ± 1.49c

PC
 Low Gleason (23) 60.86 19.12 ± 1.63 39.13 14.44 ± 1.56b 82.6 23.87 ± 1.85c
 Medium Gleason (51) 70.58 18.36 ± 2.38 39.21 19.08 ± 2.16c 82.35 23.79 ± 2.11c
 High Gleason (21) 57.14 18.07 ± 1.94 42.85 18.45 ± 1.75c 100 27.78 ± 1.91d

Average optical densities were evaluated only in patients showing positive immunoreactions. Statistical analysis refers to each antibody separately. Values denoted by different superscripts are significantly different from each other. Significance was determined by the one way ANOVA test at p ≤ 0.05, by multiple pairwise comparisons (GraphPad PRISMA 3.0 computer program).

HHS Vulnerability Disclosure